Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Dise… Read more
Supernus Pharmaceuticals Inc (SUPN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.059x
Based on the latest financial reports, Supernus Pharmaceuticals Inc (SUPN) has a cash flow conversion efficiency ratio of -0.059x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-61.66 Million) by net assets ($1.05 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Supernus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Supernus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Supernus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Supernus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Veracyte Inc
NASDAQ:VCYT
|
0.036x |
|
Silergy Corp
TW:6415
|
0.009x |
|
Tibet Huayu Mining Co Ltd
SHG:601020
|
0.047x |
|
Steadfast Group Limited
F:1S6
|
0.055x |
|
AVIC Heavy Machinery Co Ltd
SHG:600765
|
0.044x |
|
Ellington Financial Inc.
NYSE:EFC-PD
|
-0.162x |
|
Plug Power Inc
NASDAQ:PLUG
|
-0.060x |
|
Wonik Ips Co. Ltd
KQ:240810
|
0.017x |
Annual Cash Flow Conversion Efficiency for Supernus Pharmaceuticals Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Supernus Pharmaceuticals Inc from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.04 Billion | $171.95 Million | 0.166x | +37.72% |
| 2023-12-31 | $921.52 Million | $111.08 Million | 0.121x | -8.56% |
| 2022-12-31 | $886.20 Million | $116.83 Million | 0.132x | -15.40% |
| 2021-12-31 | $815.85 Million | $127.13 Million | 0.156x | -16.14% |
| 2020-12-31 | $744.86 Million | $138.40 Million | 0.186x | -22.70% |
| 2019-12-31 | $595.43 Million | $143.13 Million | 0.240x | -15.57% |
| 2018-12-31 | $453.02 Million | $128.99 Million | 0.285x | -33.57% |
| 2017-12-31 | $267.48 Million | $114.64 Million | 0.429x | +23.01% |
| 2016-12-31 | $191.75 Million | $66.81 Million | 0.348x | +28.94% |
| 2015-12-31 | $118.88 Million | $32.12 Million | 0.270x | +149.34% |
| 2014-12-31 | $71.35 Million | $7.73 Million | 0.108x | +106.26% |
| 2013-12-31 | $33.46 Million | $-57.95 Million | -1.732x | -111.22% |
| 2012-12-31 | $57.57 Million | $-47.20 Million | -0.820x | +78.60% |
| 2011-12-31 | $9.44 Million | $-36.19 Million | -3.832x | -621.85% |
| 2010-12-31 | $-44.32 Million | $-32.54 Million | 0.734x | +271.61% |
| 2009-12-31 | $-6.16 Million | $2.63 Million | -0.428x | -109.74% |
| 2008-12-31 | $-6.75 Million | $-29.65 Million | 4.395x | -- |